Log in to search using one of your social media accounts:

 

Invega Sustenna (Paliperidone Palmitate Extended-Release Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 20, 2017 Category: Drugs & Pharmacology Source Type: news

Invega Trinza (Paliperidone Palmitate Extended-release Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 31, 2016 Category: Drugs & Pharmacology Source Type: news

Janssen-Cilag receives EC approval for Trevicta for maintenance treatment of schizophrenia
Johnson & Johnson subsidiary Janssen-Cilag International has been granted approval by the European Commission (EC) for the use of Trevicta (paliperidone palmitate a three-monthly injection) for the maintenance treatment of schizophrenia in adult pati… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 1, 2016 Category: Pharmaceuticals Source Type: news

Invega Trinza (Paliperidone Palmitate Extended-release Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2016 Category: Drugs & Pharmacology Source Type: news

Janssen submits European extension marketing authorisation application for paliperidone palmitate
First long-acting treatment to be administered four times a year for the treatment of schizophrenia in adults (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 26, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Psychiatry Patient care antipsychotic Latest News long-acting therapy paliperidone palmitate schizophrenia xeplion Source Type: news

Invega Trinza (paliperidone palmitate) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 4, 2015 Category: Drugs & Pharmacology Source Type: news

Invega Trinza (paliperidone palmitate) for the Treatment for Schizophrenia
Invega Trinza (paliperidone palmitate), an atypical antipsychotic, is a three-month injection that is the first, and only, four-times-a-year drug indicated to treat schizophrenia . (Source: Drug Development Technology)
Source: Drug Development Technology - May 27, 2015 Category: Pharmaceuticals Source Type: news

INVEGA TRINZA (Paliperidone Palmitate) Injection, Suspension, Extended Release [Janssen Pharmaceuticals, Inc]
Updated Date: May 27, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - May 27, 2015 Category: Drugs & Pharmacology Source Type: news

FDA OKs 3-Month Paliperidone Injection for Schizophrenia FDA OKs 3-Month Paliperidone Injection for Schizophrenia
The quarterly treatment for schizophrenia must be preceded by monthly injections of Invega Sustenna for at least 4 months. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 19, 2015 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

Janssen seeks FDA approval for its antipsychotic drug to treat schizophrenia
Janssen Research & Development has submitted a new drug application (NDA) for its three-month atypical antipsychotic paliperidone palmitate to the US Food and Drug Administration (FDA). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 20, 2014 Category: Pharmaceuticals Source Type: news

Antipsychotic medications for schizophrenia compared: Similar results
Among adults with schizophrenia or schizoaffective disorder, treatment with the newer, more costly antipsychotic paliperidone palmitate, compared with the older antipsychotic haloperidol decanoate, found no significant difference on a measure of effectiveness, according to a recent study. Long-acting injectable antipsychotic medications are prescribed to reduce nonadherence to drug therapy and relapse in people diagnosed with a schizophrenia-spectrum disorder. The relative effectiveness of long-acting injectable versions of second-generation and older antipsychotic medications has not been previously assessed. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 20, 2014 Category: Science Source Type: news

Long-Acting Treatments for Schizophrenia
Schizophrenia has long presented treatment challenges for both patients who have the mental illness and the treatment providers who want to help them. Many medications prescribed for schizophrenia have traditionally not always been well-tolerated in patients, with sometimes significant side effects in some. Schizophrenia is a condition characterized by the person experiencing hallucinations and/or delusions, sometimes of a persecutory nature. It is usually first diagnosed in young adulthood — typically in a person’s 20s — and more often among men than women. Although usually severe in nature, it is also a...
Source: Psych Central - May 17, 2014 Category: Psychiatry Authors: John M. Grohol, Psy.D. Tags: Antipsychotics Atypical Antipsychotics Disorders General Medications Schizophrenia Treatment Invega Sustenna lai long-acting injectables Medication Noncompliance Paliperidone Psychiatry Psychotic relapse Risperidone Schizophr Source Type: news

Janssen submits sNDAs to FDA for Invega Sustenna to treat schizoaffective disorder
Janssen Pharmaceuticals has submitted supplemental new drug applications (sNDAs) to the US Food and Drug Administration (FDA) seeking approval for its once-monthly atypical long-acting antipsychotic Invega Sustenna (paliperidone palmitate) to treat s… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 13, 2014 Category: Pharmaceuticals Source Type: news

Long-acting Paliperidone Safe, Effective for Dual PsychosisLong-acting Paliperidone Safe, Effective for Dual Psychosis
Switching patients with dual psychosis from other long-acting and oral antipsychotic medications to long-acting injectable paliperidone palmitate is safe and effective, a small study suggests. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 11, 2014 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Janssen reports PALMFlexS trial results of schizophrenia drug Xeplion
Janssen Pharmaceutica has reported encouraging results from the PALMFlexS study, which demonstrated the efficacy, safety and tolerability of Xeplion (paliperidone palmitate) in patients with schizophrenia at various stages of the disease. (Source: Drug Development Technology)
Source: Drug Development Technology - December 2, 2013 Category: Pharmaceuticals Source Type: news

Paliperidone palmitate: efficacy and cost effectiveness
Any treatment that offers even a small advantage in preventing relapse in schizophrenia must be clinically and economically advantageous. Paliperidone palmitate long-acting injection might be just such a treatment (Source: Pharmacy Europe)
Source: Pharmacy Europe - October 2, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news

Flexible-Dose Injectable Effective for Acute SchizophreniaFlexible-Dose Injectable Effective for Acute Schizophrenia
Flexible dosage of the injectable atypical antipsychotic paliperidone palmitate may be effective and well tolerated in patients with acute schizophrenia unsuccessfully treated with oral antipsychotics. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 11, 2013 Category: Consumer Health News Tags: Psychiatry News Source Type: news